Hydroxysafflor yellow A protects methylglyoxal-induced injury in the cultured human brain microvascular endothelial cells

Neuroscience Letters

Volumn 549, Issue , 2013, Pages 146-150

  Li, Wenlu ^a   Liu, Jie ^a   He, Ping ^a   Ni, Zhenzhen ^a   Hu, Yangmin ^a   Xu, Huimin ^a   Dai, Haibin ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Apoptosis; Human brain microvascular endothelial cells; Hydroxysafflor yellow A; Methylglyoxal

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADVANCED GLYCATION END PRODUCT; CASPASE 3; HYDROXYSAFFLOR YELLOW A; LACTATE DEHYDROGENASE; LIPOCORTIN 5; METHYLGLYOXAL; NEUROPROTECTIVE AGENT; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN CELL; CELL DAMAGE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROVASCULAR ENDOTHELIAL CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAFFLOWER; STAINING; WESTERN BLOTTING;

ADVANCED GLYCATION END-PRODUCTS; APOPTOSIS; HUMAN BRAIN MICROVASCULAR ENDOTHELIAL CELLS; HYDROXYSAFFLOR YELLOW A; METHYLGLYOXAL;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRAIN; CASPASE 3; CELL LINE; CELL SURVIVAL; CHALCONE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; L-LACTATE DEHYDROGENASE; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRUVALDEHYDE; QUINONES;

EID: 84880751260     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.06.007     Document Type: Article

References (31)

1. Artenie A., Artenie R., Ungureanu D., Haulica I., Artenie V. [Implication of methylglyoxal in diabetes mellitus]. Rev. Med. Chir. Soc. Med. Nat. Iasi 2003, 107:727-732.
2. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40:405-412.
3. Bie X.D., Han J., Dai H.B. Effects of hydroxysafflor yellow A on the experimental traumatic brain injury in rats. J. Asian Nat. Prod. Res. 2010, 12:239-247.
4. Bucala R., Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv. Pharmacol. 1992, 23:1-34.
5. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. U S A 1993, 90:6434-6438.
6. Che W., Asahi M., Takahashi M., Kaneto H., Okado A., Higashiyama S., Taniguchi N. Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells. The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes. J. Biol. Chem. 1997, 272:18453-18459.
7. Dai H., Yu Z., Fan X., Liu N., Yan M., Chen Z., Lo E.H., Hajjar K.A., Wang X. Dysfunction of annexin A2 contributes to hyperglycemia-induced loss of human endothelial cell surface fibrinolytic activity. Thromb. Haemost. 2013, 109:1070-1078.
8. Edelstein D., Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992, 41:26-29.
9. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W., Smith S.C., Sowers Jr., J.R. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
10. Kaji Y., Amano S., Usui T., Oshika T., Yamashiro K., Ishida S., Suzuki K., Tanaka S., Adamis A.P., Nagai R., Horiuchi S. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:521-528.
11. Li J., Zhang S., Lu M., Chen Z., Chen C., Han L., Zhang M., Xu Y. Hydroxysafflor yellow A suppresses inflammatory responses of BV2 microglia after oxygen-glucose deprivation. Neurosci. Lett. 2013, 535:51-56.
12. Lok J., Sardi S.P., Guo S., Besancon E., Ha D.M., Rosell A., Kim W.J., Corfas G., Lo E.H. Neuregulin-1 signaling in brain endothelial cells. J. Cereb. Blood Flow Metab. 2009, 29:39-43.
13. Martin A., Komada M.R., Sane D.C. Abnormal angiogenesis in diabetes mellitus. Med. Res. Rev. 2003, 23:117-145.
14. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. (London) 1994, 87:21-29.
15. Munch G., Westcott B., Menini T., Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 2012, 42:1221-1236.
16. Neaton J.D., Wentworth D.N., Cutler J., Stamler J., Kuller L. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann. Epidemiol. 1993, 3:493-499.
17. Ni Z., Zhuge Z., Li W., Xu H., Zhang Z., Dai H. Inhibitory effects of hydroxysafflor yellow A on the formation of advanced glycation end products in vitro. Biol. Pharm. Bull. 2012, 35:2050-2053.
18. Odani H., Shinzato T., Matsumoto Y., Usami J., Maeda K. Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem. Biophys. Res. Commun. 1999, 256:89-93.
19. Phillips S.A., Thornalley P.J. Formation of methylglyoxal and d-lactate in human red blood cells in vitro. Biochem. Soc. Trans. 1993, 21:163S.
20. Rahbar S., Kumar Yernini K., Scott S., Gonzales N., Lalezari I. Novel inhibitors of advanced glycation endproducts. Biochem. Biophys. Res. Commun. 1999, 262:651-656.
21. Rahbar S., Yerneni K.K., Scott S., Gonzales N., Lalezari I. Novel inhibitors of advanced glycation endproducts (part II). Mol. Cell Biol. Res. Commun. 2000, 3:360-366.
22. Rojas A., Morales M.A. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci. 2004, 76:715-730.
23. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 2011, 32:763-777.
24. Sun L., Yang L., Xu Y.W., Liang H., Han J., Zhao R.J., Cheng Y. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res. 2012, 1473:227-235.
25. Vander Jagt D.L., Robinson B., Taylor K.K., Hunsaker L.A. Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. J. Biol. Chem. 1992, 267:4364-4369.
26. Wei X., Liu H., Sun X., Fu F., Zhang X., Wang J., An J., Ding H. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci. Lett. 2005, 386:58-62.
27. Wu C.H., Yen G.C. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J. Agric. Food Chem. 2005, 53:3167-3173.
28. Xiang M., Yang M., Zhou C., Liu J., Li W., Qian Z. Crocetin prevents AGEs-induced vascular endothelial cell apoptosis. Pharmacol. Res. 2006, 54:268-274.
29. Yabe-Nishimura C., Nishinaka T., Iwata K., Seo H.G. Up-regulation of aldose reductase by the substrate, methylglyoxal. Chem. Biol. Interact. 2003, 143-144:317-323.
30. Yamada H., Miyata S., Igaki N., Yatabe H., Miyauchi Y., Ohara T., Sakai M., Shoda H., Oimomi M., Kasuga M. Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. J. Biol. Chem. 1994, 269:20275-20280.
31. Zhu H., Wang Z., Ma C., Tian J., Fu F., Li C., Guo D., Roeder E., Liu K. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies. Planta Med. 2003, 69:429-433.